Irreversible Electroporation of the Hepatobiliary System: Current Utilization and Future Avenues

Govindarajan Narayanan1,2,3, Yilun Koethe4, Nicole Gentile1

  • 1Miami Cancer Institute, Baptist Health South Florida, Miami, FL 33176, USA.

PubMed

Insights

Irreversible electroporation (IRE) offers a novel, non-thermal approach for liver cancer treatment, effectively destroying tumors near sensitive structures. This method shows promise for patients unsuitable for surgery or traditional thermal ablation.

Area of Science:

  • Oncology
  • Medical Physics
  • Hepatology

Background:

  • Liver cancer is a major global health concern with limited curative options.
  • Surgical resection is effective but only feasible for a small subset of patients.
  • Thermal ablation is limited by proximity to vital structures due to heat sink effects and potential thermal damage.

Purpose of the Study:

  • To evaluate Irreversible electroporation (IRE) as a non-thermal ablative treatment for liver cancer.
  • To highlight IRE's efficacy in treating tumors near sensitive structures like vascular and biliary ducts.
  • To review the safety and efficacy profile of IRE in clinical practice for liver cancer.

Main Methods:

  • Utilizing short pulses of high-frequency energy to induce irreversible pores in cell membranes.
  • Employing a non-thermal ablation technique to target tumor cells.
  • Clinical application and review of existing studies on IRE for liver cancer.

Main Results:

  • IRE effectively destroys tumor cells by inducing apoptosis via electroporation.
  • Minimal damage to adjacent vascular and biliary structures is achieved.
  • Clinical use over a decade demonstrates an acceptable safety profile and high efficacy rates for liver cancer treatment.

Conclusions:

  • Irreversible electroporation is a viable and effective non-thermal ablative treatment for liver cancer.
  • IRE overcomes limitations of thermal ablation, particularly for tumors near critical anatomical structures.
  • IRE presents a safe and effective therapeutic option for a broader range of liver cancer patients.